Angiogenesis is an essential step in the repair process that occurs after injury. In this study, we investigated whether the angiogenic thymic peptide thymosin β4 (Tβ4) enhanced wound healing in a rat full thickness wound model. Addition of Tβ4 topically or intraperitoneally increased reepithelialization by 42% over saline controls at 4 d and by as much as 61% at 7 d post-wounding. Treated wounds also contracted at least 11% more than controls by day 7. Increased collagen deposition and angiogenesis were observed in
Angiogenesis is an essential step in the repair process that occurs after injury. In this study, we investigated whether the angiogenic thymic peptide thymosin β4 (Tβ4) enhanced wound healing in a rat full thickness wound model. Addition of Tβ4 topically or intraperitoneally increased reepithelialization by 42% over saline controls at 4 d and by as much as 61% at 7 d post-wounding. Treated wounds also contracted at least 11% more than controls by day 7. Increased collagen deposition and angiogenesis were observed in I njury initiates a complex series of events. An essential step in wound repair is angiogenesis, the formation of new blood vessels from existing blood vessels. New vessels are necessary for supplying nutrients and oxygen to the cells involved in the repair process, for removing debris, and for granulation tissue formation. These blood vessels are a transient response to the injury. Many new blood vessels form early, approximately 2 d after injury in normal wound healing, and then atrophy when healing is complete. The factors involved in triggering formation and regression of the vessels are not clear. Known angiogenic factors such as vascular endothelial growth factor, basic fibroblast growth factor, transforming growth factor α and β, and thymosin β4 (Tβ4) (Arnold et al, 1987; Dvonch et al, 1992; Frohm et al, 1996) have been found in wound fluid, but their actions in the angiogenic response are not well defined. There is some evidence from recent studies with neutralizing antibodies that basic fibroblast growth factor and vascular endothelial growth factor contribute to an angiogenic response after injury (Broadley et al, 1989; Nissen et al, 1998) .
Here we studied the effect of Tβ4 on wound healing. Tβ4 is a 43 amino acid, 4.9 kDa ubiquitous polypeptide found at concentrations of 1 ϫ 10 -5 to 5.6 ϫ 10 -1 M in a variety of tissues and cell types and was originally isolated from bovine thymus (Weber et al, 1992; Pantaloni and Carlier, 1993; Mihelic and Voelter, 1994; Oates and Goldstein, 1995) . Tβ4 can interact with G-actin and is a major actin sequestering protein in cells (Cassimeris et al, 1992; Sanders et al, 1992; Yu et al, 1993 Yu et al, , 1994 Safer and Nachmias, 1994; Sanger et al, 1995) . Tβ4 influences T cell differentiation (Hu Manuscript received October 28, 1998; revised May 6, 1999 Low et al, 1981; Low and Goldstein, 1982) and appears to play a role in the differentiation of other cell types. Endothelial cell differentiation, in part, appears to be regulated by Tβ4. Matrigel, a basement membrane matrix, stimulates the expression of Tβ4 mRNA several fold in human umbilical vein endothelial cells (Grant et al, 1995) . Tβ4 also stimulates endothelial cell migration in vitro and in vivo, acting as a potent chemoattractive factor (Malinda et al, 1997) . In addition, Tβ4 mRNA levels are elevated in areas of active neuronal growth and differentiation and around blood vessels (Carpinterio et al, 1995) , and as granulocytes and other hemopoetic cells mature (Gondo et al, 1987; Hall, 1991; GomezMarquez et al, 1989) . The ability of Tβ4 to influence the differentiation and migration of endothelial cells and the differentiation of other cell types suggests that Tβ4 may be a useful agent to treat wounds. Furthermore, Tβ4 levels are highest in platelets (Weber et al, 1992) , which are the first cells to enter the wound. Due to the potential effects angiogenic compounds may have on stimulating wound healing, we have been studying the effects of angiogenic thymic peptides on tissue repair. We investigated the ability of Tβ4 to influence wound healing using full thickness punch wounds in rat skin. Tβ4 stimulated wound healing when applied either topically or injected intraperitoneally. Reepithelialization and wound contraction were enhanced in treated wounds as early as 4 d post-wounding. Further analysis showed that capillary ingrowth is increased in treated wounds as is collagen deposition/ accumulation. Boyden chamber assays in vitro showed that Tβ4 stimulates keratinocyte migration. We conclude that Tβ4 has potent wound healing effects in addition to angiogenesis and may be useful in the clinic to treat normal and chronic wounds.
MATERIALS AND METHODS
Cell culture Primary keratinocytes were prepared from either BALB/C or CD-1 newborn mice as described previously (Dlugosz et al, 1995) . Cells were plated in calcium-and magnesium-free Eagle's minimal essential medium (EMEM) containing 8% fetal calf serum treated with 8% Chelex (Bio-Rad Laboratories, Hercules, CA), 20 units penicillin-streptomycin per ml, and the calcium concentration was adjusted to 0.25 mM. The following day, cultures were washed with calcium-and magnesium-free phosphate-buffered saline, treated briefly with Trypsin (Life Technologies, Gaithersburg, MD), washed in culture medium, and resuspended in EMEM (Life Technologies, Gaithersburg, MD) containing 0.05 mM calcium (cells and media gifts of Laura Hansen, NCI, NIH). Cells were used immediately in migration assays.
In vivo wound assay Six full thickness 8 mm punch biopsy wounds were made on the dorsal surface of each rat as previously described (Bhartiya et al, 1992; Sidhu et al, 1996) . Tβ4 (synthetic GMP material, gift from Alpha 1 Biomedical, Bethesda, MD) was applied topically at the time of wounding (5 µg in 50 µl) and again after 48 h to three of the wounds on each rat. Controls for the topical treatment (the three remaining wounds on each rat) received identical amounts of saline at the time of wounding and at 48 h. Alternatively, three rats received intraperitoneal injections of Tβ4 (60 µg in 300 µl) at the time of wounding and every other day thereafter for 7 d. Controls for these animals received identical amounts of saline intraperitoneally on the same injection schedule. At days 4 and 7 post-wounding, wound tissue was collected and fixed in 10% buffered formalin (intraperitoneal, n ϭ 18 samples; topical, n ϭ 9 samples). The samples were sectioned, and sections from the middle of the wound were stained with hematoxylin and eosin and Masson's Trichrome (American Histolabs, Gaithersburg, MD). This experiment was performed twice using three rats for each test condition.
Morphometric measurements Histologic sections were used to measure the reepithelialization and the contraction of the wound using an ocular micrometer. Epidermal migration was determined by measuring the lengths of the tongues of epithelium migrating from either side of the wound over the wound bed from the zone of proliferation at the margin of the uninjured and wounded skin. Epidermal thickness was also measured beginning at the junction of the uninjured and proliferating epidermis. The thickness was measured vertically from the basement membrane to the most superficial layer of the migrating epidermis at every 200 microns. The mean epidermal thickness of each migrating tongue of epidermis was then computed for each wound. Vessel counts were performed by first identifying vascular spaces by their endothelial lining. All such vessels in the wound bed were counted, including those at the junction of the dermis and the subcutis, since angiogenesis into the wounds occurs to a great extent from these vessels. The numbers were averaged into vessel counts per 10 high powered fields (40ϫ).
Migration assay Keratinocyte migration assays were carried out in Boyden chambers using 12 µm pore polyester membranes (Poretics, Livermore, CA) coated with 0.1 mg per ml solution of collagen IV in dH 2 O (Trevigen, Gaithersburg, MD). Filters were then dried for at least 1 h. Cells were harvested using Versene or Trypsin (Life Technologies, Gaithersburg, MD) and resuspended in EMEM with 0.05 mM Ca 2ϩ . The bottom chamber was loaded with EMEM containing 0.01, 0.1, 10, 100, and 1000 ng synthetic Tβ4 (gift from Alpha 1 Biomedical, Bethesda, MD) per ml. Conditioned medium from primary dermal fibroblasts (gift from Laura Hansen, NCI, NIH) and/or keratinocyte growth factor (gift of Don Bottaro, NCI, NIH) was added to several wells as a positive control. Cells were added to the upper chamber at a concentration of 50,000 cells per well. Chambers were incubated at 35°C/7% CO 2 for 4-5 h and the filters were then fixed and stained using Diff-Quik (Baxter Healthcare Corporation, McGraw Park, IL). The cells that migrated through the filter were quantitated by counting the center of each well at 10ϫ using an Olympus CK2 microscope. Each condition was assayed in triplicate wells and each experiment was repeated four times with different preparations of cells. This trend continued to termination at day 7 (*p ഛ 0.04, Student's t-test). Measurements are expressed as the mean % decrease Ϯ SEM: day 4, n ϭ 8; day 7, control, n ϭ 7; treated, n ϭ 5. (b) Intraperitoneal injection of Tβ4 (60 µg in 300 µl) on the day of wounding and subsequently every other day also resulted in a 42% (Ϯ9%) decrease in gap size relative to saline-treated controls. This decrease was observed on the fourth day post-wounding and continued through day 7 (**p ഛ 0.0007, Student's t-test). Measurements are expressed as the mean % decrease Ϯ SEM: day 4, control, n ϭ 16; treated, n ϭ 18; day 7, control, n ϭ 14; treated, n ϭ 16.
RESULTS

Reepithelialization and contraction of treated wounds
The effect of Tβ4 on wound healing was studied in a full thickness cutaneous rat wound model. Figure 1 shows a diagram of the wound site that extends from the epidermis to the fat/muscle layer. This model allowed measurement of two parameters: the reepithelialization (gap) and the contraction (width) of the wound. Wounds treated topically with Tβ4 (5 µg per 50 µl) showed a 18% (Ϯ12%) decrease in gap as compared with saline-treated control wounds as early as 4 d after injury (Fig 2a, n ϭ 8 evaluable  wounds) . This increase in reepithelialization was also observed in wounds treated for 7 d and the rate of gap closure was slightly accelerated over that observed at day 4. A 62% (Ϯ21%) decrease in gap size was observed in the Tβ4-treated wounds (p ഛ 0.04). Quantitation of epidermal migration showed a statistically significant 1.5-fold increase in migration of epidermal tongues over the wound bed after topical treatment ( Table 1) . Intraperitoneal injection of Tβ4 (60 µg per 300 µl) also resulted in enhanced wound healing. Statistically significant differences were observed between the control injections (saline, n ϭ 16 evaluable) and the Tβ4 injections (n ϭ 18) (Fig 2b) . There was a 42% (Ϯ9%) decrease in gap size at day 4 with Tβ4 treatment (p ഛ 0.0007). At day 7, a 61% (Ϯ11%) decrease in gap size was observed as compared with the control (n ϭ 16 evaluable wounds Tβ4; 14 controls) (p ഛ 0.0002). Quantitation of epidermal migration in intraperitoneally treated wounds showed a statistically significant increase in migration of epidermal tongues as compared with controls ( Table 1) . There was no apparent difference in the thickness of the migrating epidermis between either of the Tβ4 treatments and the control ( Table 1) . Histologic sections of the wounds clearly show increased reepithelialization in the treated wounds as compared with controls in 7 d wounds (Fig 3b and c vs a) .
Contraction (width) of the wounds was also evaluated in both topically and intraperitoneally treated wounds. After 4 d of Tβ4 treatment, wounds showed a 15% (Ϯ7%) decrease in width as compared with controls (Fig 4a, n ϭ 8 evaluable wounds) and after 7 d a 24% (Ϯ8%) decrease was observed (n ϭ 5 Tβ4; seven controls). Intraperitoneal injections of Tβ4 resulted in an 18% (Ϯ4%) decrease in wound width as compared with controls on day 4 and an 11% (Ϯ4%) decrease on day 7 (Fig 4b) . These data demonstrate that Tβ4, when given either topically or systemically, increases wound reepithelialization and contraction. Both topical and systemic treatments appear to be equally effective. Lower doses of Tβ4 were tested, including 2.5 µg and 0.5 µg in 50 µl for topical and 30 µg and 6 µg in 300 µl for intraperitoneal injection, but reduced or no effect, respectively, was observed on wound healing (data not shown).
Granulation tissue in treated wounds
Granulation tissue is composed of new blood vessels, fibroblasts, collagen, and macrophages. Because Tβ4 treatment enhanced wound healing, we investigated which of the cell types involved in the granulation tissue might be effected by treatment. Previous work had shown that Tβ4 is a potent angiogenic factor acting as a specific chemoattractive factor for endothelial cells and stimulating in vivo angiogenesis in the subcutaneous mouse Matrigel plug model (Malinda et al, 1997) . We investigated whether the healing wounds showed any increase in angiogenesis. Figure 3 shows a comparison of typical control (d ) and Tβ4-treated (e and f ) sections of 7 d wounds. Treatment with Tβ4 resulted in considerable capillary ingrowth (Fig 3e and  f, arrows) . Vessel counts showed a significant (almost 2-fold) increase in the number of vessels in Tβ4-treated wounds ( Table 1) . No increases in the number of macrophages in the wounds were observed, agreeing with previous in vitro findings that Tβ4 did not stimulate macrophage migration. We did observe an increase in the accumulation/biosynthesis of collagen in treated Tβ4-wounds (Fig 5b and c vs a) supporting the observation of decreased wound width and suggesting a role for Tβ4 in wound contraction. Both the topical and the systemically treated wounds appeared similar, although the wound contraction proceeded slightly more quickly with the topical treatment. Thus, Tβ4 appears to stimulate some of the cells/processes involved in granulation tissue formation, including angiogenesis and collagen deposition.
Keratinocyte migration in vitro Previously we had found that Tβ4 promoted endothelial cell migration but did not effect fibroblasts, smooth muscle, neutrophil, or monocyte migration (Malinda et al, 1997) . Based on the rapid reepithelialization observed with Tβ4 treatment, we next tested the effect of Tβ4 on keratinocyte migration in vitro. Boyden chamber assays with two types of mouse keratinocytes demonstrated that the cells migrated in response to Tβ4 after 4-5 h. Migration was enhanced 2-3-fold (p ഛ 0.003) over migration in the presence of media alone (Fig 6) and the maximal responding doses exceeded the positive control. The effect of Tβ4 on migration, while showing slightly differing dose curves depending on the cell preparation and source, clearly showed a biphasic pattern with 1000 ng per ml and 0.01 ng per ml showing the most migration and the middle doses showing less stimulation (but still greater than control media) in all four assays.
DISCUSSION
Angiogenic factors can potentially enhance repair in both chronic and acute wounds. We have been analyzing thymic peptides to determine if these potent angiogenic factors play a role in healing. Thymosin α1 has been previously identified as an angiogenic factor that stimulates healing in rats (Malinda et al, 1998) . Another thymic µl on the day of wounding and every 48 h, resulted in a 15% decrease in wound width as compared with the saline controls as early as 4 d after wounding and continued until day 7. Measurements are expressed as the mean % decrease Ϯ SEM: day 4, n ϭ 8; day 7, control, n ϭ 7; treated, n ϭ 5. (b) Intraperitoneal injection of Tβ4 60 µg in 300 µl on the day of wounding and every other day resulted in a 18% decrease in wound width relative to saline-treated controls. This trend was observed on the fourth day post-wounding and continued through day 7 (*p ഛ 0.0001, **p ഛ 0.08, significant difference from media alone, Student's t-test). Measurements are expressed as the mean % decrease Ϯ SEM: day 4, control, n ϭ 16; treated, n ϭ 18; day 7, control, n ϭ 14; treated, n ϭ 16. peptide, Tβ4, was also found to be an angiogenic factor, specifically stimulating endothelial cell migration. Both are active at the 1 ng per ml level for endothelial cell migration in the Boyden chamber assay (Malinda et al, 1997 (Malinda et al, , 1998 . Tβ4 also stimulated in vivo migration/angiogenesis and was found to be upregulated 4-6-fold after endothelial cells have begun to make capillary-like structures on Matrigel. In this study, we report the effect of Tβ4 on wound healing in a rat full thickness cutaneous wound model.
The initial studies using the punch wound model in normal rats showed that Tβ4 significantly stimulated wound closure. Stimulation was observed starting as early as 4 d post-wounding and proceeded at an accelerated rate through termination of the experiment at 7 d. Both topical application and intraperitoneal injection were equally effective in stimulating reepithelialization as measured by gap closure at day 7. When wound contraction was assessed, topical application appeared to be slightly more effective based on day 7 post-wounding measurements (24% decrease vs 18% decrease). The potent nature of local application is especially significant in that it would be easier to administer and would prevent any possible side-effects of systemic neovascularization.
Histologic observation also showed that treated wounds were healing faster than control wounds. At days 4 (data not shown) and 7, significantly more blood vessels were observed in both the topically and the intraperitoneally treated wounds. As blood vessels are an essential early response to wounding, increased neovascularization resulting from Tβ4 may be one of the factors responsible for enhanced healing. Tβ4 has been previously identified in wound fluid (Frohm et al, 1996) and is present in high concentrations (as high as 560 µm) (Weber et al, 1992) in platelets. Because platelets are the first cells to arrive at the site of injury and are responsible for releasing chemoattractive factors to attract monocytes and neutrophils to begin repair, they may also actively release Tβ4 that attracts endothelial cells and promotes angiogenesis. Additionally, we observed the increased deposition of well-organized collagen. This additional collagen in the treated wounds may explain the increased contraction observed, and may also affect the tensile strength of the wound. It is not clear if the increased collagen is due to the better supply of nutrients from the vessels or if Tβ4 affects collagen synthesis. Further studies are necessary to determine the effects of Tβ4 on collagen production.
The increased gap closure observed in treated wound appears, in part, to be due to Tβ4 promoting keratinocyte migration. Boyden chamber assays demonstrate that Tβ4 stimulates migration at as low as 0.01 ng per ml and with concentrations as high as 1 µg per ml. Less migration was observed at the 0.1-10 ng per ml range. The biphasic nature of the keratinocyte response to Tβ4 was highly reproducible and may relate to differences in the amount of Tβ4 present during the normal wound healing process. It is possible that Tβ4 is released at high concentrations at the time of injury by platelets. The keratinocytes could initially respond to the Tβ4 by migrating into the wound. Levels of Tβ4 could then maintain keratinocyte migration into the wound. Stimulation at very low levels could be useful in promoting a migratory response in keratinocytes farther away from the injury site. In preliminary experiments, we also observed that Tβ4 enhanced wound healing in an impaired model. Steroid-treated rats showed a significant increase in the level of healing when Tβ4 was added topically or injected intraperitoneally (data not shown). At the initial time point, day 4, topically treated animals showed little response (ഛ7% gap or width closure, n ϭ 3) compared with saline treatment. Intraperitoneal injection, however, resulted in a 28% (Ϯ12%, n ϭ 10 treated, five controls) decrease in gap size and a 14% (Ϯ6%) decrease in wound width. At day 7, response was observed with both topical treatment and intraperitoneal injection. The gap in topically treated animals decreased by 39% (Ϯ31%, n ϭ 6) compared with saline treatment. The wound width decreased by 23% (Ϯ12%). Intraperitoneal injection resulted in a 26% (Ϯ14%, n ϭ 10) decrease in gap size and a 10% (Ϯ5%) decrease in wound width. Taken together, these results suggest that Tβ4 may be a useful addition to the treatment of chronic, as well as acute wounds.
Tβ4 has a number of characteristics unlike other angiogenic wound factors. First of all, Tβ4 does not promote cell growth but only appears to affect cell migration. Tβ4 has no signal sequence (Gondo et al, 1987) but is found in serum (Naylor et al, 1984; Weller et al, 1988) . This may be due to its small size, which allows it to diffuse out of cells that produce it, or because it is released by damaged or dying cells (Gomez-Marquez et al, 1989) . It does not appear to bind heparin or other matrix molecules, suggesting it can rapidly diffuse throughout tissues. Currently, no receptors have been identified. Tβ4 is also a very potent migration factor with activity at 1 ng (for endothelial cells) or 10 pg (for keratinocytes). The potent effects of intraperitoneally injected Tβ4 support its high diffusibility in tissues. Based on a previous study where thymosin α1 was also found to promote wound repair, we believe that the thymic peptides may represent a new class of potent wound healing agents that may be of clinical importance. 
